Staff and students at the University of Manchester have been recognised for their role in helping to establish the Alderley Park Lighthouse Laboratory in Cheshire.
A partnership between the University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.
Scientists at the Alderley Park Lighthouse Lab in Cheshire have revealed the speed and scale at which the new variant of the COVID virus is spreading through communities across the country.
Scientists at the Alderley Park Lighthouse Lab in Cheshire processed their 6 millionth test over the festive period, the equivalent of providing tests for one in ten people in the UK.
Active Needle Technology, Xerion Healthcare and Medicines Discovery Catapult win funding to begin ground-breaking project.
Intelligent OMICS, Arctoris and Medicines Discovery Catapult test in silico pipeline for identifying new molecules for cancer treatment.
The Catapult Network launched today the 2019-2020 Annual Report – Creating the future through innovation: Recovery and Resilience.
Optibrium, Intellegens and Medicines Discovery Catapult combine their expertise in drug discovery and AI research.
Dr Sally Price, Head of Cell and Translational Science at Medicines Discovery Catapult (MDC) has been named in BioBeat’20 Movers & Shakers in BioBusiness 2020.
Today, the University of Exeter and Medicines Discovery Catapult (MDC) announce their strategic partnership to accelerate medicines Research & Development (R&D), creating value for the sector and enhancing translational skills.
See how we can help support you with your next drug discovery project.
Speak to us